Studies of urinary cystine precipitation in vitro: ontogeny of cystine nephrolithiasis and identification of meso-2,3-dimercaptosuccinic acid as a potential therapy for cystinuria

Abstract

Children with fully recessive (Type I/I) cystinuria have a high risk of stone formation in the first decade of life. To assess the tendency for cystine to precipitate in individual urine samples, we developed an in vitro assay in which radiolabelled cystine (4 mM) was dissolved in urine at 37 °C after alkalization to pH 10. Samples were then brought to pH 5, cooled, and centrifuged. The % decrease in supernatant cpm was used as a measure of cystine precipitation (CP). CP varied widely among normal children (74% ± 34) whereas variability of repeated determinations on a single adult individual was modest (64% ± 3.3). The assay was used to compare various potential therapies for cystinuria. Precipitation of exogenous cystine from normal urine was strongly inhibited by addition of d-penicillamine (CP: 8% ± 3) or dimercaptosuccinic acid (DMSA) (CP: 5% ± 1), at urinary concentrations attained by standard oral doses of each drug. Mercaptopropionylglycine (MPG) was moderately effective (CP: 43% ± 9), whereas captopril was a weak inhibitor (CP: 63% ± 12). Precipitation of endogenous cystine (2191 μmol/L) from a cystinuric patient showed that DMSA and d-penicillamine were again highly effective compared to the other agents. In addition DMSA and penicillamine added to the same patient’s urine reduced the free cystine by 50% (as measured by automated amino acid analyzer) whereas MPG and captopril had no effect. In conclusion, DMSA is comparable to d-penicillamine as an in vitro inhibitor.